ImmunityBio IBRX Q2 2026: ANKTIVA Revenue Surges 94%, EPS Miss Explained

ImmunityBio reported Q2 2026 revenue of $51.24 million, beating the $49.70 million consensus estimate by roughly 3%. That figure marks the eighth consecutive quarter of sequential revenue gains for ANKTIVA, the company's flagship bladder cancer therapy, with sales up 94% compared to the same period a year ago. The revenue trajectory has been steep: ANKTIVA generated just $1.05 million in Q2 2024, and has climbed steadily to $51.24 million by Q2 2026.

The headline EPS miss — a reported loss of $0.22 against an estimated loss of $0.08, a gap of 175% — was driven by non-cash charges tied to warrant and derivative fair value adjustments linked to the stock's own price appreciation. Because those charges move with the share price rather than with the underlying business, they can distort the bottom line without reflecting a deterioration in operations. Investors focused on the commercial trajectory of ANKTIVA may look through that accounting noise.

The next major catalyst on the calendar is an FDA decision on a broader bladder cancer label, currently set for January 6, 2027. An expanded indication could meaningfully widen the addressable patient population for ANKTIVA and accelerate the revenue growth that has already defined the past eight quarters.